Drugs in R & D

, Volume 8, Issue 6, pp 400–402 | Cite as

MN 001

KCA 757, KCA-757, MN-001
Adis R&D Profile
  • 24 Downloads

Keywords

Interstitial Cystitis Obstructive Airway Disease Moderate Asthma Late Asthmatic Response Methacholine Challenge Test 

References

  1. 1.
    Technology Vision Group LLC. BioPartnering North America. 4th Annual BioPartnering North America: 5 Feb 2006Google Scholar
  2. 2.
    MediciNova Inc. MediciNova Announces the Completion of Enrollment of a Phase II Study for Its Novel, Oral Asthma Treatment. Media Release: 7 Sep 2005. Available from URL: http://www.medicinova.com Google Scholar
  3. 3.
    MediciNova Inc. MediciNova Announces the Initiation of the Phase III Clinical Program for MN-001, a Novel Oral Treatment for Bronchial Asthma. Media Release: 16 Nov 2006. Available from URL: http://www.medicinova.com Google Scholar
  4. 4.
    Busse WW, Nelson HS, Korenblat PE, et al. Effects of MN-001 in patients with mild-to-moderate asthma in a randomized, double-blind and placebo-controlled phase II study. Journal of Allergy and Clinical Immunology 119 (Suppl.): 5, No. 1, Jan 2007CrossRefGoogle Scholar
  5. 5.
    MediciNova Inc. MediciNova Announces Positive Clinical Results With MN-001 in a Phase II Asthma Trial. Media Release: 14 Dec 2005. Available from URL: http://www.medicinova.com Google Scholar
  6. 6.
    MediciNova Inc. MediciNova Reports 2006 Financial Results Six Compounds Advancing Through Clinical Trials. Media Release: 15 Feb 2007. Available from URL: http://www.medicinova.com Google Scholar
  7. 7.
    MediciNova Inc. MediciNova Announces Notice of Allowance for Two Key Patent Applications for MN-001. Media Release: 4 Jan 2006. Available from URL: http://www.medicinova.com Google Scholar
  8. 8.
    Locke KW. Phase I study of MN-001, an oral anti-inflammatory agent for the treatment of asthma. Journal of Allergy and Clinical Immunology 115 (Suppl.): 151 (plus poster), abstr. 603, No. 2, Feb 2005CrossRefGoogle Scholar
  9. 9.
    Uno T, Toru T, Namiki H. Pharmacological profile of KCA-757, a novel anti-asthmatic drug. 3. Pharmacological activities of KCA-907, a major metabolite of KCA-757. XV International Congress of Allergology and Clinical Immunology (Suppl. 2): 281, 1994Google Scholar
  10. 10.
    Ohashi M, Uno T, Namiki H. Pharmacological profile of KCA-757, a novel anti-asthmatic drug. 2. Effects on bronchial hyperreactivity and late asthmatic response in guinea pigs. XV International Congress of Allergology and Clinical Immunology (Suppl. 2): 281, 1994Google Scholar
  11. 11.
    Ohashi M, Uno T, Kishi T. Pharmacological profile of KCA-757, a novel anti-asthmatic drug. 1. Effects on LTD4-and antigen-induced bronchoconstriction in guinea pigs. XV International Congress of Allergology and Clinical Immunology (Suppl. 2): 281, 1994Google Scholar
  12. 12.
    MediciNova Inc. MediciNova Announces Results From a Phase II/III Interstitial Cystitis Trial With MN-001. Media Release: 16 Jan 2007. Available from URL: http://www.medicinova.com Google Scholar

Copyright information

© Adis Data Information BV 2007

Personalised recommendations